MedTrace Logo

Titratable Dosing in Moderate to Severe Asthmatics

NCT00651768 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 570

Last updated 2011-01-24

No results posted yet for this study

Summary

The purpose of this study is to compare the long term safety of Symbicort with budesonide alone, in adolescents and adults with asthma.

Conditions

Interventions

DRUG

budesonide/formoterol

DRUG

Symbicort pMDI + budesonide HFA pMDI

Symbicort 2 X 160/4.5mcg \& budesonide HFA pMDI 4 X 160mcg

Sponsors & Collaborators

Principal Investigators

  • Catherine Bonuccelli · AstraZeneca

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
12 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-08-31
Completion
2005-01-31

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00651768 on ClinicalTrials.gov